Gobernado M, Canton E
Drugs. 1985;29 Suppl 5:24-31. doi: 10.2165/00003495-198500295-00007.
The antibacterial activity of temocillin, a novel beta-lactam antibiotic, was tested against 796 clinical isolates. We also conducted a comparative study against 8 other antibiotics. Temocillin exhibited good activity against Gram-negative organisms including Escherichia coli, and the genera Proteus, Enterobacter, Serratia, Klebsiella, Citrobacter, Providencia, Salmonella, Shigella and Haemophilus: 98% of the strains were inhibited by concentrations less than or equal to 16 mg/L. The results of this in vitro study and temocillin's favourable pharmacokinetic properties suggest that temocillin is a very promising penicillin for the treatment of hospital infections caused by Gram-negative organisms.
新型β-内酰胺类抗生素替莫西林的抗菌活性针对796株临床分离菌进行了测试。我们还针对其他8种抗生素进行了对比研究。替莫西林对革兰氏阴性菌具有良好活性，包括大肠杆菌以及变形杆菌属、肠杆菌属、沙雷氏菌属、克雷伯菌属、柠檬酸杆菌属、普罗威登斯菌属、沙门氏菌属、志贺氏菌属和嗜血杆菌属：98%的菌株可被浓度小于或等于16mg/L的药物抑制。这项体外研究结果以及替莫西林良好的药代动力学特性表明，替莫西林是一种治疗革兰氏阴性菌引起的医院感染非常有前景的青霉素类药物。
